Company press releases and official corporate announcements.
A centralized feed of corporate press releases, earnings announcements, mergers, and official statements. Content is presented for informational purposes and may require additional analysis for market relevance.
23,751 total articles
United Fire Group, Inc. announced it will release its first quarter 2026 earnings results after market close on May 5, 2026, followed by an earnings call on May 6. The company invites analysts, investors, and stakeholders to participate via teleconference or webcast. The event will be archived for replay and a transcript will be available. United F…
Revolution Medicines announced that detailed results from its pivotal Phase 3 RASolute 302 clinical trial of daraxonrasib, an oral RAS(ON) multi-selective inhibitor, in previously treated metastatic pancreatic ductal adenocarcinoma patients, will be presented at the 2026 ASCO Annual Meeting. The topline data showed statistically significant and cli…
Northeast Bank announced it will release its fiscal 2026 third quarter earnings on April 27, 2026, followed by a conference call on April 28, 2026. The call will be hosted by senior executives and available via live webcast and phone. Northeast Bank operates as a national lender and community bank, focusing on commercial real estate loans and small…
Alexander's, Inc., a New York City-based real estate investment trust, will release its Q1 2026 earnings on May 4, 2026, before market open. Vornado Realty Trust, the manager of Alexander's operations, will host a conference call on May 5, 2026, discussing quarterly results including those related to Alexander's. The company highlighted typical for…
Black Diamond Therapeutics announced multiple presentations at the 2026 ASCO Annual Meeting showcasing Phase 2 data of their brain-penetrant EGFR inhibitor, Silevertinib, in non-small cell lung cancer (NSCLC) and glioblastoma (GBM) patients. Early data indicate promising efficacy and safety profiles, including a 60% objective response rate in front…
Vornado Realty Trust announced it will release its first quarter 2026 earnings report on May 4, 2026, after the NYSE closes. The company will host a conference call and webcast on May 5, 2026 to discuss the quarterly results. Forward-looking statements highlight risks related to interest rate fluctuations, inflation, and their potential impact on t…
Regeneron Pharmaceuticals reported positive Phase 3 NIMBLE trial results for cemdisiran, an investigational siRNA therapy targeting complement factor 5 (C5), demonstrating rapid, deep, and sustained disease control in adults with generalized myasthenia gravis (gMG). The trial met primary and key secondary endpoints at 24 weeks, showing significant …
Zentalis Pharmaceuticals announced that an abstract highlighting results from Part 1 of their MUIR trial, testing azenosertib in combination with paclitaxel for platinum-resistant ovarian cancer, has been accepted for presentation at the ASCO 2026 Annual Meeting. Azenosertib, a first-in-class WEE1 inhibitor, is being developed as a biomarker-driven…
Skyworks Solutions, Inc. will release its second quarter fiscal 2026 earnings on May 5, 2026, followed by a conference call to discuss results and business outlook. The company provides analog and mixed-signal semiconductors across various sectors including wireless networking, aerospace, automotive, and consumer electronics.
Immatics N.V. announced that four abstracts from its clinical cell therapy and bispecific T-cell engager pipeline have been selected for oral presentations at the 2026 ASCO Annual Meeting. Data highlights include Phase 1b results of anzu-cel in melanoma, updated Phase 1a/b data for second-generation IMA203CD8 in gynecologic cancers, findings on PRA…
Aprea Therapeutics announced that early results from their first-in-human Phase 1 trial of the WEE1 inhibitor APR-1051 in advanced solid tumor patients have been accepted for presentation at the 2026 ASCO Annual Meeting. This milestone highlights progress in developing targeted therapies for biomarker-defined cancers and underscores the company's f…
NextCure, Inc. announced that Phase 1 clinical data for SIM0505, an investigational antibody drug conjugate targeting Cadherin-6 for the treatment of advanced solid tumors, will be presented at ASCO 2026. The results underscore forward progress in NextCure's oncology pipeline, focusing on innovative therapies for cancer including difficult-to-treat…
IP Strategy Holdings, Inc. has announced a 1-for-20 reverse stock split of its common stock effective April 23, 2026, aimed at complying with Nasdaq's minimum bid price requirements and improving stock liquidity. The reverse split will adjust shares and outstanding warrants proportionately without affecting authorized shares or shareholder rights e…
Cellectar Biosciences announced that a subset of data from their CLOVER WaM clinical trial involving iopofosine I-131 was accepted for presentation at the 2026 American Society of Clinical Oncology Annual Meeting. The data focuses on relapsed/refractory Waldenström macroglobulinemia (WM) patients who have progressed after treatment with BTK inhibit…
Progress Software released its 2025 Corporate Social Responsibility report showcasing a strong commitment to employee development, community engagement, and environmental sustainability. The report details expanded professional growth programs, support for global charitable initiatives especially in STEM education, and steps toward enhanced environ…
Disc Medicine announced that it will present new data from the RALLY-MF Phase 2 trial of DISC-0974, an investigational treatment for anemia in myelofibrosis patients, at the American Society of Clinical Oncology Annual Meeting in June 2026. Initial trial results showed unprecedented anemia response rates in a hard-to-treat population, with updated …
Cardiff Oncology announced it will present updated interim results from its Phase 2 trial evaluating onvansertib in combination with standard chemotherapy regimens for first-line treatment of RAS-mutated metastatic colorectal cancer. The presentation at ASCO 2026 underscores onvansertib's potential as a novel oral PLK1 inhibitor addressing a signif…
Holley Performance Brands (NYSE: HLLY) announced the launch of Holley High-Performance Car Care, a new line of automotive detailing products developed in partnership with Malco Automotive. This new product line expands Holley's American Performance chemicals portfolio into vehicle appearance care, targeting performance enthusiasts seeking high-qual…
SoundHound AI (Nasdaq: SOUN) announced it will acquire LivePerson (Nasdaq: LPSN) in a strategic transaction combining their voice AI and digital messaging capabilities. The deal aims to create a comprehensive, end-to-end omnichannel conversational AI platform serving over 25 Fortune 100 companies, with expanded vertical reach and significant revenu…
Edible Garden AG Incorporated announced a significant expansion of its fresh-cut herb supply to Target stores, increasing its retail footprint and expected to boost revenue growth. The company emphasizes its advanced controlled environment agriculture technology, sustainable operations, and patented innovations in farming and displays. This expande…
Silynxcom Ltd., a manufacturer of ruggedized tactical communication headsets, announced it received a $500,000 purchase order from a new military customer in Asia. The order furthers the company's expansion into the Asian defense market with their advanced in-ear tactical headset systems featuring superior noise reduction, 'hear-thru' technology, a…
SEALSQ Corp announces significant advancements in embedding Post-Quantum Cryptography (PQC) directly into semiconductor hardware to counter emerging AI-driven cybersecurity threats, highlighted by recent breakthroughs like Anthropic's Claude Mythos. The company emphasizes that hardware-based quantum-resistant cryptography offers superior protection…
Virtuix Inc. demonstrated its Virtual Terrain Walk (VTW) full-body VR system at the 4th Annual Immersive Technology Summit in Orlando before senior U.S. Department of Defense officials. The technology enables military personnel to rehearse missions in photorealistic, geo-specific virtual environments with unrestricted movement. This event highlight…
PacBio announced that Lucid Genomics has joined its Compatible partner program to provide tertiary analysis solutions optimized for PacBio's HiFi long-read sequencing technology. This partnership aims to streamline genomic data interpretation and accelerate the transition from sequencing results to actionable biological insights, benefiting researc…
Outlook Therapeutics announced the completion of a Federal Dispute Resolution meeting with the FDA concerning its biologics license application for ONS-5010/LYTENAVA™, an ophthalmic formulation of bevacizumab for treating wet age-related macular degeneration. The meeting aimed to seek alignment on the regulatory pathway after a Complete Response Le…
